{
    "clinical_study": {
        "@rank": "88925", 
        "arm_group": [
            {
                "arm_group_label": "A (MAGIC)", 
                "arm_group_type": "Experimental", 
                "description": "MAGIC regimen: Arm A consists of 3 cycles of chemotherapy pre-surgery and a further 3 cycles of chemotherapy post-surgery. Each cycle of chemotherapy lasts 21 days/3 weeks. The drugs used in the MAGIC regimen include Epirubicin, Cisplatin and 5-Flourouracil/ Capecitabine"
            }, 
            {
                "arm_group_label": "B (CROSS)", 
                "arm_group_type": "Experimental", 
                "description": "Arm B consists of the CROSS protocol, which includes a combination of chemotherapy and radiotherapy prior to surgery. The patient will receive 5 weeks of radiation therapy and 5 weekly cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 5 weeks as follows: days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31 inclusive. The chemotherapy and radiotherapy will run concurrently over a 5-week period. Chemotherapy is given by intravenous infusion on days 1, 8, 15, 22 and 29."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      To evaluate one, two and three year survival of patients treated with resection plus\n      neoadjuvant and adjuvant chemotherapy versus resection plus neoadjuvant chemo radiotherapy.\n\n      Secondary Objective(s):\n\n      To evaluate the effect of both neoadjuvant regimens on clinical and pathological response\n      rate (in particular relief of dysphagia, improvement in health related quality of life\n      (HRQL), endoscopic regression, and CT-PET evidence of tumour response), tumour regression\n      grade, node-positivity, post-operative pathology, disease-free survival, time to treatment\n      failure, toxicity, post-operative complications and Health Related Quality of Life (HRQL).\n\n      Exploratory Objective(s):\n\n      Translational Research: The collection of blood and tissue samples for storage in the bio\n      bank for future research."
        }, 
        "brief_title": "MAGIC vs. CROSS Upper GI. ICORG 10-14, V3", 
        "condition": [
            "Adenocarcinoma of the Oesophagus", 
            "Adenocarcinoma of the Oesophago-gastric Junction", 
            "Oesophageal Tumours", 
            "Junctional Tumours", 
            "Oesophageal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Esophageal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Indication:\n\n      Patients with cT2-3 N0-1 M0 adenocarcinoma of the oesophagus or junction, based on clinical,\n      CT-PET, and EUS staging, will be randomised to the MAGIC chemotherapy regimen versus the\n      CROSS neoadjuvant chemo radiation protocol prior to surgery. Patients will be randomised to\n      either Arm A (MAGIC regimen of chemotherapy only and surgery) or Arm B (CROSS protocol:\n      chemotherapy with radiation therapy and surgery as per multimodal protocol).\n\n      Eligible patients will be randomised in a 1:1 fashion between the MAGIC regimen or the CROSS\n      protocol.\n\n      Exploratory Study- Translational Research :\n\n      All patients enrolled in this trial, will be invited to consent to having some of their\n      tissue and blood taken for use in future research studies. Following consent from the\n      patient, tissue biopsy of tumour and/or normal oesophageal tissue will be obtained for\n      research at the same time as that biopsied for histological diagnosis. In addition, tumour\n      and/or normal tissue will also be obtained following surgical resection. Patient blood\n      samples will also be obtained, both before and during treatment. The identification of both\n      tumour and circulating biomarkers will increase knowledge of the molecular mechanism(s)\n      underlying treatment response in oesophageal cancer and may facilitate the identification of\n      biomarkers predicting patient response to treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically verified adenocarcinoma of the oesophagus or oesophago-gastric\n             junction.\n\n          2. CT- 18FDG-PET and EUS in all patients\n\n          3. Staging laparoscopy will be performed for tumours of the abdominal oesophagus,\n             junction and proximal stomach i.e. AEG II and AEG III (at the investigators\n             discretion)\n\n          4. Pre-treatment stage cT2-3, N0-1, M0\n\n          5. No prior abdominal or thoracic radiotherapy\n\n          6. Male/female patients aged >18 years.\n\n          7. WHO Performance Status 0, 1 or 2\n\n          8. ASA I-II\n\n          9. Completion of baseline quality of life questionnaire (EORTC QLQ C30).\n\n         10. Adequate cardiac function. Patients with a cardiac history should have a cardiology\n             review and should have a left ventricular ejection fraction > 50% (as determined by\n             MUGA scan or ECHO).\n\n         11. Adequate respiratory function. Patients should have pulmonary function tests\n             completed with FEV1 > 1.5L\n\n         12. Adequate bone marrow function: absolute neutrophil count (ANC) >1.5x10^9/l; white\n             blood cell count >3x10^9/l; platelets >100x10^9/l; haemoglobin (Hb) >9g/dl (can be\n             post-transfusion).\n\n         13. Adequate renal function: glomerular filtration rate >60ml/minute (calculated or\n             measured).\n\n         14. Adequate liver function: serum bilirubin <1.5x ULN; AST <2.5x ULN and ALP <3x ULN\n             (ULN as per institutional standard)\n\n         15. Written informed consent must be obtained from the patient before any study-trial\n             specific procedures are performed.\n\n        Exclusion Criteria:\n\n          1. Tumours of squamous histology.\n\n          2. Patients with advanced inoperable or metastatic oesophageal, junctional or gastric\n             adenocarcinoma.\n\n          3. Any prior chemotherapy for gastrointestinal cancer.\n\n          4. Prior abdominal or thoracic radiation.\n\n          5. Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary\n             artery disease or myocardial infarction within the last 12 months. Patients with any\n             history of clinically significant cardiac failure are excluded from study entry.\n\n          6. Clinical COPD with significant obstructive airways disease classified by FEV1 < 1.5 L\n             or PaO2 less than 9kPa on room air\n\n          7. Known peripheral neuropathy >Grade 1 (absence of deep tendon reflexes as the sole\n             neurological abnormality does not render the patient ineligible).\n\n          8. Known positive tests for human immunodeficiency virus (HIV) infection, , acute or\n             chronic active hepatitis B infection.\n\n          9. Any other malignancies within the last 5 years (other than curatively treated basal\n             cell carcinoma of the skin and/or in situ carcinoma of the cervix)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "366", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01726452", 
            "org_study_id": "ICORG 10-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "A (MAGIC)", 
                "description": "50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)", 
                "intervention_name": "Epirubicin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "A (MAGIC)", 
                "description": "60mg/m2 on day 1 of each cycle only (i.e. every 21 days).", 
                "intervention_name": "Cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "A (MAGIC)", 
                "description": "5 Flourouracil(200 mg/m2/Day)as a continuous intravenous infusion every day for 21 days/3 weeks, Capecitabine (625 mg/m2 twice daily orally)for 21 days/3 weeks. The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator. 5 Flourouracil/ Capecitabine are given daily for the duration of each cycle (i.e. for 9 weeks pre-surgery and for 9 weeks post-surgery).", 
                "intervention_name": "5 Flourouracil/ Capecitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B (CROSS)", 
                "description": "patient will receive 5 weeks of radiation therapy (41.4 Gy/23 fractions).", 
                "intervention_name": "(41.4 Gy/23 fractions)", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "B (CROSS)", 
                "description": "50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine given IV half an hour before commencing Paclitaxel.Once the Paclitaxel infusion is completed NACL 0.9%,100 ml will be infused IV over half an hour.After this infusion is completed Ondansetron or its equivalent diluted in 100mls NACL 0.9% will be given IV over half an hour on Days 1, 8, 15, 22 and 29.", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B (CROSS)", 
                "description": "Dose determined as per calculation,infused on Days 1, 8, 15, 22 and 29.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Capecitabine", 
                "Cisplatin", 
                "Epirubicin", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 24, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Contact person", 
                    "phone": "021-4271971"
                }, 
                "facility": {
                    "address": {
                        "city": "Cork", 
                        "country": "Ireland"
                    }, 
                    "name": "Cork University Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact person", 
                    "phone": "01 410 3000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "St. James's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact person", 
                    "phone": "(01) 809 3000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "Beaumont Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact person", 
                    "phone": "01 4065000"
                }, 
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "Ireland"
                    }, 
                    "name": "SLRON- St Luke's Radiation Oncology Network"
                }, 
                "investigator": {
                    "last_name": "Donal Hollywood, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Contact person", 
                    "phone": "(0)91 524222"
                }, 
                "facility": {
                    "address": {
                        "city": "Galway", 
                        "country": "Ireland"
                    }, 
                    "name": "Galway University Hospital"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Ireland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (MAGIC Regimen) vs. Neoadjuvant Chemoradiation (CROSS Protocol) in Adenocarcinoma of the Oesophagus and Oesophago-gastric Junction", 
        "overall_official": {
            "affiliation": "Trinity Centre, St. James's Hospital, Dublin 8", 
            "last_name": "John V. Reynolds, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ireland: Irish Medicines Board"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2024", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall survival will be calculated from the date of randomisation and an event registered on the date of death from any cause. Patients lost to follow up, or those with no death recorded on the day the database is frozen, will be censored on the date of last follow up.", 
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "At end of trial- up to 3 years in follow up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01726452"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "ICORG- All Ireland Cooperative Oncology Research Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ICORG- All Ireland Cooperative Oncology Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}